Top 10 Cancer Currents Blog Posts of 2018

Having trouble viewing this email? View it as a Web page.

With 2018 drawing to a close, we took a look back at the Cancer Currents posts published over the last 12 months. As our coverage shows, 2018 has been a year of important advances in cancer research. Some of our most-read posts were those about new treatment options for a variety of cancers, including childhood cancers. But posts about the side effects of cancer treatment and the cost of cancer drugs also received great interest. In case you missed them when they were first posted or you want to read them again or share them with a friend, here are our top 10 most-read posts of 2018. Thank you again for your interest and support. We hope you'll continue to read the blog and encourage others to subscribe. Wishing you a happy and healthy holiday season, The Cancer Currents editorial team   Altering Chemotherapy Improves Outcomes in Early-Stage Pancreatic Cancer June 28, 2018 For people with early-stage pancreatic cancer, results from two clinical trials suggest that altering the type and timing of chemotherapy improves survival. The findings will likely change the standard of care. The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr. Judith Paice July 16, 2018 The opioid epidemic is having a significant impact on cancer patients, says Dr. Judith Paice of Northwestern University. She explains how oncologists can address concerns about opioid misuse when managing cancer pain. Can Immunotherapy Succeed Against Glioblastoma? May 24, 2018 Researchers are hopeful that, for the deadly brain cancer glioblastoma, immunotherapy might succeed where other therapies have not. Different immunotherapy approaches are being tested in clinical trials. Oncolytic Virus Therapy: Using Tumor-Targeting Viruses to Treat Cancer February 9, 2018 Cancer treatments known as oncolytic viruses are being tested in clinical trials, and one, T-VEC or Imlygic®, has been approved by the FDA. Research now suggests that these treatments work not only by infecting and killing tumor cells, but that they may also be a form of cancer immunotherapy. Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer August 29, 2018 A new study shows that 90% of postmenopausal women diagnosed with endometrial cancer reported vaginal bleeding before their diagnosis. Approximately 9% of women who saw a doctor for bleeding, the study showed, later received an endometrial cancer diagnosis. The Imperative of Addressing Cancer Drug Costs and Value March 15, 2018 The President's Cancer Panel has released its report, Promoting Value, Affordability, and Innovation in Cancer Drug Treatment. The report recommends six actions to maximize the value and affordability of cancer drug treatment. Selumetinib Continues to Show Promise in Children with NF1 June 8, 2018 The investigational drug selumetinib shrank tumors in some children with a genetic syndrome called neurofibromatosis type 1 (NF1). The drug also improved symptoms related to tumors known as neurofibromas, which can cause pain, difficulty breathing or walking, and disfigurement. Gut Bacteria May Influence Effectiveness of a Type of Immunotherapy February 5, 2018 Three new studies have identified intestinal bacteria that appear to influence the response to checkpoint inhibitors. Researchers think their findings could be used to improve patients' responses to these immunotherapy drugs. Study Identifies Potential Cause of Hearing Loss from Cisplatin January 26, 2018 The chemotherapy drug cisplatin is retained in the inner ear for long periods, possibly explaining the hearing loss linked to treatment with the drug. Combination of Immunotherapy Drugs Approved for Metastatic Colorectal Cancer August 3, 2018 The combination of the immune checkpoint inhibitors ipilimumab (Yervoy) and nivolumab (Opdivo) has been approved by FDA for the treatment of patients with metastatic colorectal cancer whose tumor cells have DNA repair defects.

 

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892